From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia | Zendy

Mohammadreza Sharifi | Zendy; Naeim Ehtesham | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia

Author(s) -

Mohammadreza Sharifi,

Naeim Ehtesham

Publication year - 2016

Publication title -

advanced biomedical research

Language(s) - English

Resource type - Journals

ISSN - 2277-9175

DOI - 10.4103/2277-9175.190996

Subject(s) - acute promyelocytic leukemia , medicine , microrna , malignancy , disease , oncology , acute leukemia , targeted therapy , bioinformatics , leukemia , cancer , biology , gene , biochemistry , retinoic acid

Acute promyelocytic leukemia (APL) is a hematopoietic malignancy that is known with its special cytogenetic feature. Several studies have surveyed expression signature of microRNAs (miRNAs) in APL patients, especially patients who are treated with conventional therapy of this disease. Using miRNAs as diagnostic or prognostic biomarkers in various cancers has been widely studied. Currently, most studies are focusing on exploiting miRNAs as therapeutic tools, and promising progress has been achieved in this field. Recently, studies in the field of miRNA-based therapy in APL have been started

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research